Browsing by Author "De Velasco, Guillermo"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Thumbnail Image
    Publication
    Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma
    (Elsevier, 2025) Rioja, Patricia; Rey-Cardenas, M; De Velasco, Guillermo
    Renal cell carcinoma (RCC) is a heterogenous disease which the incidence is increasing worldwide. The identification and understanding of the role of the Von Hipple Lindau (VHP) in regulating the hypoxia-inducible factor signaling pathway has revolutionized the treatment of this disease. Belzutifan is an oral hypoxiainducible factor (HIF)-2α inhibitor, which has demonstrated efficacy in treating von Hippel-Lindau (VHL) disease and for the treatment of adults with RCC who experienced disease progression after PD-1/PD-L1– and VEGFR-targeted therapies. One of the most common adverse effect of this drug is anemia; however, it is treatment is not well known. This review summarizes role of the VHL-HIF pathway in ccRCC aroused the interest of targeting HIF activity, the history of belzutifan development and their relationship to anemia as well as propose a management algorithm